Drug · FAERS side-effect profile with label screen
Deoxycholic Acid side effects: what 60 FDA adverse event reports show
Drug class
No validated FDA label found
Who reports
60 reports · 75% serious · 7 with death outcome · 60% female
openFDA FAERS counts, all years, deduplication not applied
Used for
—
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation.
Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)?
That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.
Causality screen of the 40 strongest signals
Reporting / coding artifact 5No label text to screen 35
What the badges mean
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
- No label text to screen No validated FDA label was retrievable for this product, so the screen could not run. Disproportionality only.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 15 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
Show:
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Injection site nodule | 121 | 100.5 84.4–119.6ROR 106.0 · χ² 11,693 / p <1e-300 | 97.9 EB05 84.1 · IC025 +5.8 3/3 methods agree | No label text to screen | – | no trial data cached |
| Nerve injury | 115 | 94.0 78.6–112.5ROR 98.9 · χ² 10,386 / p <1e-300 | 91.7 EB05 78.4 · IC025 +5.7 3/3 methods agree | No label text to screen | – | no trial data cached |
| Injection site induration | 86 | 60.3 48.9–74.2ROR 62.5 · χ² 4,922 / p <1e-300 | 59.1 EB05 49.4 · IC025 +5.1 3/3 methods agree | No label text to screen | – | no trial data cached |
| Injection site swelling | 305 | 36.5 32.8–40.5ROR 41.8 · χ² 10,479 / p <1e-300 | 36.2 EB05 33.0 · IC025 +4.9 3/3 methods agree | No label text to screen | – | no trial data cached |
| Nodule | 45 | 31.2 23.4–41.7ROR 31.8 · χ² 1,282 / p 4e-281 | 30.7 EB05 23.9 · IC025 +4.1 3/3 methods agree | No label text to screen | – | no trial data cached |
| Tenderness | 33 | 28.6 20.4–40.2ROR 29.0 · χ² 849 / p 5e-187 | 28.1 EB05 20.9 · IC025 +3.8 3/3 methods agree | No label text to screen | – | no trial data cached |
| Swelling | 262 | 25.4 22.6–28.5ROR 28.5 · χ² 6,122 / p <1e-300 | 25.3 EB05 22.8 · IC025 +4.4 3/3 methods agree | No label text to screen | – | no trial data cached |
| Injection site mass | 103 | 25.3 20.9–30.5ROR 26.4 · χ² 2,375 / p <1e-300 | 25.1 EB05 21.3 · IC025 +4.2 3/3 methods agree | No label text to screen | – | no trial data cached |
| Injection site discolouration | 31 | 22.6 15.9–32.1ROR 22.9 · χ² 618 / p 1e-136 | 22.3 EB05 16.4 · IC025 +3.5 3/3 methods agree | No label text to screen | – | no trial data cached |
| Hypoaesthesia oral | 34 | 20.4 14.6–28.5ROR 20.7 · χ² 607 / p 2e-134 | 20.2 EB05 15.0 · IC025 +3.4 3/3 methods agree | No label text to screen | – | no trial data cached |
| Injection site discomfort | 21 | 18.4 12.0–28.2ROR 18.5 · χ² 328 / p 2e-73 | 18.0 EB05 12.2 · IC025 +3.0 3/3 methods agree | No label text to screen | – | no trial data cached |
| Product administered at inappropriate site | 27 | 13.4 9.2–19.6ROR 13.6 · χ² 298 / p 4e-67 | 12.9 EB05 9.0 · IC025 +2.8 3/3 methods agree | Reporting / coding artifact | – | no trial data cached |
| Pain in jaw | 34 | 10.8 7.8–15.1ROR 11.0 · χ² 294 / p 4e-66 | 10.3 EB05 7.5 · IC025 +2.7 3/3 methods agree | No label text to screen | – | no trial data cached |
| Mass | 16 | 10.3 6.3–16.8ROR 10.4 · χ² 125 / p 2e-29 | 9.0 EB05 5.5 · IC025 +2.2 3/3 methods agree | No label text to screen | – | no trial data cached |
| Paraesthesia oral | 16 | 10.1 6.2–16.4ROR 10.1 · χ² 122 / p 1e-28 | 8.7 EB05 5.4 · IC025 +2.1 3/3 methods agree | No label text to screen | – | no trial data cached |
| Deformity | 10 | 9.6 5.2–17.9ROR 9.7 · χ² 69 / p 5e-17 | 7.6 EB05 4.1 · IC025 +1.7 3/3 methods agree | No label text to screen | – | no trial data cached |
| Scab | 12 | 9.6 5.4–16.8ROR 9.6 · χ² 84 / p 3e-20 | 7.8 EB05 4.5 · IC025 +1.9 3/3 methods agree | No label text to screen | – | no trial data cached |
| Paralysis | 15 | 9.4 5.7–15.6ROR 9.5 · χ² 105 / p 7e-25 | 8.0 EB05 4.9 · IC025 +2.0 3/3 methods agree | No label text to screen | – | no trial data cached |
| Injection site bruising | 76 | 8.7 7.0–10.9ROR 9.0 · χ² 512 / p 1e-113 | 8.4 EB05 6.9 · IC025 +2.7 3/3 methods agree | No label text to screen | – | no trial data cached |
| Pallor | 25 | 8.3 5.6–12.2ROR 8.4 · χ² 153 / p 2e-35 | 7.5 EB05 5.2 · IC025 +2.2 3/3 methods agree | No label text to screen | – | no trial data cached |
| Contusion | 85 | 8.0 6.5–9.8ROR 8.2 · χ² 514 / p 4e-114 | 7.7 EB05 6.4 · IC025 +2.6 3/3 methods agree | No label text to screen | – | no trial data cached |
| Swelling face | 51 | 7.1 5.4–9.3ROR 7.2 · χ² 261 / p 6e-59 | 6.7 EB05 5.3 · IC025 +2.3 3/3 methods agree | No label text to screen | – | no trial data cached |
| Injection site warmth | 16 | 7.0 4.3–11.4ROR 7.1 · χ² 77 / p 1e-18 | 6.0 EB05 3.9 · IC025 +1.7 3/3 methods agree | No label text to screen | – | no trial data cached |
| Skin ulcer | 19 | 6.6 4.2–10.4ROR 6.7 · χ² 86 / p 1e-20 | 5.8 EB05 3.9 · IC025 +1.8 3/3 methods agree | No label text to screen | – | no trial data cached |
| Hypoaesthesia (numbness) | 110 | 6.6 5.5–8.0ROR 6.9 · χ² 523 / p 4e-116 | 6.5 EB05 5.5 · IC025 +2.4 3/3 methods agree | No label text to screen | – | no trial data cached |
| Incorrect route of product administration | 12 | 6.4 3.7–11.3ROR 6.5 · χ² 50 / p 8e-13 | 5.3 EB05 3.2 · IC025 +1.4 3/3 methods agree | Reporting / coding artifact | – | no trial data cached |
| Scar | 12 | 6.3 3.6–11.1ROR 6.3 · χ² 49 / p 2e-12 | 5.2 EB05 3.2 · IC025 +1.4 3/3 methods agree | No label text to screen | – | no trial data cached |
| Lymphadenopathy | 23 | 5.9 3.9–8.8ROR 5.9 · χ² 88 / p 3e-21 | 5.3 EB05 3.7 · IC025 +1.7 3/3 methods agree | No label text to screen | – | no trial data cached |
| Skin discolouration | 29 | 5.7 4.0–8.2ROR 5.8 · χ² 108 / p 1e-25 | 5.3 EB05 3.8 · IC025 +1.8 3/3 methods agree | No label text to screen | – | no trial data cached |
| Injection site pain (pain where injected) | 191 | 5.7 5.0–6.5ROR 6.1 · χ² 742 / p 1e-163 | 5.6 EB05 5.0 · IC025 +2.2 3/3 methods agree | No label text to screen | – | no trial data cached |
| Injection site rash | 19 | 5.7 3.6–8.8ROR 5.7 · χ² 68 / p 7e-17 | 5.0 EB05 3.4 · IC025 +1.6 3/3 methods agree | No label text to screen | – | no trial data cached |
| Muscle tightness | 10 | 5.6 3.0–10.4ROR 5.6 · χ² 33 / p 4e-9 | 4.5 EB05 2.7 · IC025 +1.1 3/3 methods agree | No label text to screen | – | no trial data cached |
| Toothache | 11 | 5.5 3.0–9.9ROR 5.5 · χ² 36 / p 1e-9 | 4.5 EB05 2.7 · IC025 +1.2 3/3 methods agree | No label text to screen | – | no trial data cached |
| Neck pain | 32 | 5.2 3.7–7.3ROR 5.2 · χ² 103 / p 1e-24 | 4.8 EB05 3.6 · IC025 +1.7 3/3 methods agree | No label text to screen | – | no trial data cached |
| Injection site erythema (redness where injected) | 64 | 4.7 3.7–6.0ROR 4.8 · χ² 183 / p 7e-42 | 4.5 EB05 3.7 · IC025 +1.8 3/3 methods agree | No label text to screen | – | no trial data cached |
| Lip swelling | 16 | 4.3 2.7–7.1ROR 4.4 · χ² 38 / p 4e-10 | 3.9 EB05 2.6 · IC025 +1.1 3/3 methods agree | No label text to screen | – | no trial data cached |
| Skin disorder | 15 | 4.1 2.5–6.7ROR 4.1 · χ² 32 / p 9e-9 | 3.7 EB05 2.4 · IC025 +1.0 3/3 methods agree | No label text to screen | – | no trial data cached |
| Drug ineffective for unapproved indication | 23 | 3.7 2.5–5.6ROR 3.8 · χ² 43 / p 2e-11 | 3.5 EB05 2.5 · IC025 +1.1 3/3 methods agree | Reporting / coding artifact | – | no trial data cached |
| Expired product administered | 13 | 3.5 2.1–6.1ROR 3.6 · χ² 21 / p 2e-6 | 3.2 EB05 2.0 · IC025 +0.8 3/3 methods agree | Reporting / coding artifact | – | no trial data cached |
| Wrong technique in product usage process | 63 | 2.8 2.2–3.6ROR 2.9 · χ² 73 / p 8e-18 | 2.8 EB05 2.2 · IC025 +1.1 3/3 methods agree | Reporting / coding artifact | – | no trial data cached |
Trial evidence (ClinicalTrials.gov)
Trial cross-check not yet run for this drug (ClinicalTrials.gov pull covers the 800 most-reported drugs first).
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Injection site swelling | 305 | 36.5 32.8–40.5ROR 41.8 · χ² 10,479 / p <1e-300 | 36.2 EB05 33.0 · IC025 +4.9 3/3 methods agree | No label text to screen | – | no trial data cached |
| Swelling | 262 | 25.4 22.6–28.5ROR 28.5 · χ² 6,122 / p <1e-300 | 25.3 EB05 22.8 · IC025 +4.4 3/3 methods agree | No label text to screen | – | no trial data cached |
| Injection site pain (pain where injected) | 191 | 5.7 5.0–6.5ROR 6.1 · χ² 742 / p 1e-163 | 5.6 EB05 5.0 · IC025 +2.2 3/3 methods agree | No label text to screen | – | no trial data cached |
| Injection site nodule | 121 | 100.5 84.4–119.6ROR 106.0 · χ² 11,693 / p <1e-300 | 97.9 EB05 84.1 · IC025 +5.8 3/3 methods agree | No label text to screen | – | no trial data cached |
| Nerve injury | 115 | 94.0 78.6–112.5ROR 98.9 · χ² 10,386 / p <1e-300 | 91.7 EB05 78.4 · IC025 +5.7 3/3 methods agree | No label text to screen | – | no trial data cached |
| Hypoaesthesia (numbness) | 110 | 6.6 5.5–8.0ROR 6.9 · χ² 523 / p 4e-116 | 6.5 EB05 5.5 · IC025 +2.4 3/3 methods agree | No label text to screen | – | no trial data cached |
| Injection site mass | 103 | 25.3 20.9–30.5ROR 26.4 · χ² 2,375 / p <1e-300 | 25.1 EB05 21.3 · IC025 +4.2 3/3 methods agree | No label text to screen | – | no trial data cached |
| Injection site induration | 86 | 60.3 48.9–74.2ROR 62.5 · χ² 4,922 / p <1e-300 | 59.1 EB05 49.4 · IC025 +5.1 3/3 methods agree | No label text to screen | – | no trial data cached |
| Contusion | 85 | 8.0 6.5–9.8ROR 8.2 · χ² 514 / p 4e-114 | 7.7 EB05 6.4 · IC025 +2.6 3/3 methods agree | No label text to screen | – | no trial data cached |
| Injection site bruising | 76 | 8.7 7.0–10.9ROR 9.0 · χ² 512 / p 1e-113 | 8.4 EB05 6.9 · IC025 +2.7 3/3 methods agree | No label text to screen | – | no trial data cached |
| Injection site erythema (redness where injected) | 64 | 4.7 3.7–6.0ROR 4.8 · χ² 183 / p 7e-42 | 4.5 EB05 3.7 · IC025 +1.8 3/3 methods agree | No label text to screen | – | no trial data cached |
| Wrong technique in product usage process | 63 | 2.8 2.2–3.6ROR 2.9 · χ² 73 / p 8e-18 | 2.8 EB05 2.2 · IC025 +1.1 3/3 methods agree | Reporting / coding artifact | – | no trial data cached |
| Swelling face | 51 | 7.1 5.4–9.3ROR 7.2 · χ² 261 / p 6e-59 | 6.7 EB05 5.3 · IC025 +2.3 3/3 methods agree | No label text to screen | – | no trial data cached |
| Nodule | 45 | 31.2 23.4–41.7ROR 31.8 · χ² 1,282 / p 4e-281 | 30.7 EB05 23.9 · IC025 +4.1 3/3 methods agree | No label text to screen | – | no trial data cached |
| Pain in jaw | 34 | 10.8 7.8–15.1ROR 11.0 · χ² 294 / p 4e-66 | 10.3 EB05 7.5 · IC025 +2.7 3/3 methods agree | No label text to screen | – | no trial data cached |
Unlabeled candidate signals
Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.
✓ A hand-written Bradford Hill causality assessment exists for this drug: Zoledronic acid (bisphosphonates) ↔ Osteonecrosis of the jaw.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Deoxycholic Acid?
In FDA FAERS, the most frequently co-reported reaction terms for Deoxycholic Acid are injection site swelling, swelling, injection site pain, injection site nodule, nerve injury, hypoaesthesia. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Deoxycholic Acid have an FDA boxed warning?
No validated FDA label could be retrieved for this product name, so this page cannot say.
Do FAERS signals prove that Deoxycholic Acid causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- No FDA label passed the name-validation check for this product string, so label-based screening was skipped
- Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 55 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath
Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.